Emmanuele Kouvousis/LinkedIn
Mar 31, 2026, 12:50
Emmanuele Kouvousis: DOAC Dose Adjustments for Older Patients
Emmanuele Kouvousis, Non-Invasive Cardiologist, Scientific Director at Affidea, shared a post on LinkedIn:
“DOAC dose adjustments for older patients
In older adults, DOAC dose adjustment is largely driven by renal function, age, and low body weight.
Below is a concise, agent-specific summary based on the provided data.
General principles in older patients
- Bleeding risk is higher in older people with renal impairment, prompting cautious dosing and regular renal monitoring on DOACs.[1]
- For all DOACs, creatinine clearance (CrCl), not eGFR, should guide dosing.[1]
Apixaban (nonvalvular AF, renal impairment table)
- Standard: 5 mg twice daily if CrCl ≥30 mL/min and ABC rule not met.[1]
- Reduce to 2.5 mg twice daily if ≥2 of: age ≥80 years, body weight ≤60 kg, serum creatinine ≥133 µmol/L (applies across CrCl ≥30).[1]
- CrCl 15–29 mL/min: 2.5 mg twice daily.[1]
- CrCl <15: not recommended/contraindicated.[1]
Dabigatran (nonvalvular AF)
- Usual: 150 mg twice daily.[1]
- If age ≥80 years or concomitant verapamil: 110 mg twice daily.[1]
- If age 75–80, CrCl 30–50, GORD, or increase bleeding risk: consider 110 mg twice daily.[1]
- CrCl <30 mL/min: not recommended/contraindicated.[1]
- Bleeding and stroke risk both increase with age >75 years.[2]
Edoxaban (nonvalvular AF)
- Standard: 60 mg once daily for CrCl >50–95 mL/min.[3]
- 30 mg once daily if CrCl 15–50 mL/min or body weight ≤60 kg or selected P‑gp inhibitors.[3][1]
- CrCl >95 mL/min: do not use (reduced efficacy vs warfarin).[3]
- CrCl <15 mL/min: insufficient data/not recommended.[3]
Rivaroxaban (nonvalvular AF)
- CrCl >50 mL/min: 20 mg once daily with evening meal.[4]
- CrCl <50 mL/min (≥15): 15 mg once daily.[4][1]
- CrCl <15 mL/min or dialysis: not recommended.[4]
Monitoring in older adults
- At least annual renal and liver monitoring, more frequently when CrCl falls into the 30s or 20s (e.g., 3‑monthly, 2‑monthly).[1
References:
- Direct Oral Anticoagulant Dosing for Stroke Prevention in People with Nonvalvular Atrial Fibrillation and Renal
- Dabigatran (Pradaxa) – Geriatric Dosing and Uses
- Edoxaban (Savaysa) – Adult Dosing and Uses
- Rivaroxaban (Xarelto) – Adult Dosing and Uses“
Stay updated with Hemostasis Today.
-
May 23, 2026, 03:55WFH Initiative Brings Hope to the Hemophilia Community in India
-
May 23, 2026, 03:47Satyam Arora: Welcoming the New ISBT Board for the 2026 Term
-
May 23, 2026, 03:33Brig Tathagata Chatterjee: Connecting With World Leaders in Hematology at ISH Congress
-
May 23, 2026, 03:18Mathangi Kumar: Dental Management Strategies for Congenital Hemophilia
-
May 23, 2026, 03:02Maitri Vaishnav: Anatomical Variability and Surgical Relevance of Corona Mortis
-
May 23, 2026, 02:26Muhammad Hashim: When the Blood Smear Told a Different Story Behind a ‘Critical’ Platelet Count
-
May 23, 2026, 02:20Augustina Isioma Ikusemoro: Understanding One of the Most Common and Preventable Transfusion Reactions
-
May 23, 2026, 02:15What’s Your Advice for the Newly Diagnosed? – ITP Support Association
-
May 23, 2026, 02:08Rob Maloney: When You Stop Building Only a Career and Start Building a Life of Significance